Janus Biotherapeutics

Janus, Roche collaborate in autoimmune diseases

Friday, August 21, 2015

Janus Biotherapeutics, a Massachusetts-based autoimmunity therapeutics company, is collaborating with Roche on the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are class of proteins in the innate immune system. Evidence links aberrant TLR activation and signaling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR R&D.

[Read More]